Lessons Learnt From the COVID-19 Pandemic.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2021
Historique:
received: 13 04 2021
accepted: 05 07 2021
entrez: 19 8 2021
pubmed: 20 8 2021
medline: 24 8 2021
Statut: epublish

Résumé

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has been characterized by unprecedented rates of spatio-temporal spread. Here, we summarize the main events in the pandemic's timeline and evaluate what has been learnt by the public health community. We also discuss the implications for future public health policy and, specifically, the practice of epidemic control. We critically analyze this ongoing pandemic's timeline and contrast it with the 2002-2003 SARS outbreak. We identify specific areas (e.g., pathogen identification and initial reporting) wherein the international community learnt valuable lessons from the SARS outbreak. However, we also identify the key areas where international public health policy failed leading to the exponential spread of the pandemic. We outline a clear agenda for improved pandemic control in the future.

Identifiants

pubmed: 34409008
doi: 10.3389/fpubh.2021.694705
pmc: PMC8365337
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

694705

Informations de copyright

Copyright © 2021 Stenseth, Dharmarajan, Li, Shi, Yang and Gao.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Lancet. 2021 May 1;397(10285):1611-1612
pubmed: 33933197
J Eval Clin Pract. 2020 Dec;26(6):1592-1598
pubmed: 32970386
Front Public Health. 2020 Nov 26;8:596944
pubmed: 33324602
Sci Adv. 2020 Jul 1;6(27):
pubmed: 32937441
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24575-24580
pubmed: 32887803
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Proc Natl Acad Sci U S A. 2020 Dec 11;:
pubmed: 33310901
Proc Biol Sci. 2019 Apr 24;286(1901):20182429
pubmed: 30991930
Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29246-29248
pubmed: 33144498
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
J Clin Invest. 2020 Jul 1;130(7):3348-3349
pubmed: 32352406
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2021 Feb 19;371(6531):
pubmed: 33323424
Virol Sin. 2020 Dec;35(6):868-874
pubmed: 32748130
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33593938
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Emerg Microbes Infect. 2021 Dec;10(1):1507-1514
pubmed: 34263709
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
BMJ. 2021 Mar 30;372:n854
pubmed: 33785519
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
PLoS Med. 2008 Jan 15;5(1):e3
pubmed: 18198939
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Biochem Biophys Res Commun. 2004 Apr 2;316(2):476-83
pubmed: 15020242
N Engl J Med. 2003 Jul 10;349(2):187-8
pubmed: 12853594
Clin Infect Dis. 2021 Jan 27;72(2):332-339
pubmed: 33501949
N Engl J Med. 2003 May 15;348(20):1995-2005
pubmed: 12671061
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
BMJ Glob Health. 2019 Nov 10;4(6):e001984
pubmed: 31799005
Lancet. 2020 Jul 4;396(10243):63-70
pubmed: 32505220
Med (N Y). 2020 Dec 18;1(1):3-8
pubmed: 33363282
PLoS Pathog. 2020 May 14;16(5):e1008421
pubmed: 32407364
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Cell. 2021 Jun 24;184(13):3438-3451.e10
pubmed: 34139177
Lancet Infect Dis. 2021 Feb;21(2):193-202
pubmed: 33729915
Science. 2003 May 30;300(5624):1394-9
pubmed: 12730500
Lancet. 2003 Apr 19;361(9366):1319-25
pubmed: 12711465
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279

Auteurs

Nils Chr Stenseth (NC)

Centre for Ecological and Evolutionary Synthesis, Department of Biosciences, University of Oslo, Oslo, Norway.

Guha Dharmarajan (G)

Savannah River Ecology Laboratory, University of Georgia, Aiken, SC, United States.

Ruiyun Li (R)

Centre for Ecological and Evolutionary Synthesis, Department of Biosciences, University of Oslo, Oslo, Norway.

Zheng-Li Shi (ZL)

CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.

Ruifu Yang (R)

State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.

George F Gao (GF)

CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Chinese Center for Disease Control and Prevention, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH